Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Petr Vachal

Pengcheng Patrick Shao

Feng Ye

Jeffrey John Hale

Jian Liu

Wanying Sun

Shouwu Miao

Deyou Sha

Vincent Colandrea

Debra L Ondeyka

Izzat Tiedje Raheem

XiaoXia Qian

Cameron James Smith

Guizhen Dong

Fengqi Zhang

Hong Li

Zhiqiang Guo

Kake Zhao

Jonathan E Wilson

Revathi Reddy Katipally

John D Schreier

George A Doherty

Jianming Bao

Peter J Sinclair

Zhijian Lu

Lin Yan

Lin Chu

Christopher Francis Thompson

Rajan Anand

James Francis Dropinski

Ramzi Farah Sweis

Yi-Heng Chen

John J Acton, Iii

Pei Huo

Timothy John Hartingh

Sriram Tyagarajan

Yi Zang

Julianne A Hunt

Ming Wang

Alexander J Kim

Ravi Kurukulasuriya

Wenlang Fu

Florida Kallashi

Joan M Pierce

Aaron Zwicker

Ning Qi

Jayanth Thiruvellore Thatal

Arto K Krikorian

Samantha E Adamson

Maud Reiter

Joan M Pierce (nee Fletcher)

Joan M Fletcher

Irene E Legiec

Leslie Toth

Compounds of Formula I: I and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines. 

Antiviral oxime phosphoramide compounds

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein D1, D2 and D3 are each N, CH, or substituted CH, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. 

Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein X is &#x2014;C(&#x2550;O) or &#x2014;S(O)&#x2014;, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. 

Bicyclic ureas and thiadiazolidine-1, 1-dioxides as CETP inhibitors

Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

Antiviral beta-amino acid ester phosphodiamide compounds

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis. The chemical compounds that are disclosed cholesterol ester transfer protein (CETP) and are expected to have utility in raising HDL-C, lowering LDL-C, and in the treatment and prevention of atherosclerosis. 

Spirocyclic CETP inhibitors

3,3'-Disubstituted indoline compounds, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.

3,3'-disubstituted indolines as inhibitors of cholesterol ester transfer protein

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein X is (CH) or O, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: 

Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis. 

Cyclic amine substituted heterocyclic CETP inhibitors

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. 

Fused bicyclic oxazolidinone CETP inhibitor

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, Ais a substituted phenyl group or indanyl group. Formula (I). 

Cyclic amine substituted oxazolidinone CETP inhibitor

Compounds having the structure of Formula Ia, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. 

Substituted benzopiperazines as CETP inhibitors

The present invention relates to substituted 1,3,8-triazaspiro[4.5]decame-2,4-diones useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones

The present invention relates to spiroazaindole compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Spiroazaindoles

The present invention relates to spiroindalone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Spiroindalones

Growing community of inventors

Summit, NJ, United States of America

Petr Vachal